TSBL-Based Versus BMI-Based Biliopancreatic Limb Length in One-Anastomosis Gastric Bypass (TSBL-OAGB)

TSBL-Based Versus BMI-Based Biliopancreatic Limb Length in One-Anastomosis Gastric Bypass: Interim Results of a Randomized Trial

This study compares two surgical techniques used during one-anastomosis gastric bypass (OAGB) surgery for patients with severe obesity. During this operation, surgeons create a bypass of part of the small intestine, and the length of this bypassed segment (called the biliopancreatic limb) affects both weight loss and the risk of nutritional side effects. In this trial, one group of patients has the limb length calculated individually based on the measured total length of their small intestine (TSBL-based method), while the other group receives a limb length based on standard body mass index (BMI) categories (BMI-based method). The study compares weight loss outcomes, improvement of obesity-related health problems, and complication rates between the two approaches over 12 months after surgery. The trial is being conducted at a single center in Almaty, Kazakhstan, and plans to enroll 100 patients total; this record reflects an interim analysis based on the first 75 patients enrolled.

Study Overview

Detailed Description

This is a single-center, prospective, randomized controlled trial comparing two methods for determining biliopancreatic limb length (BPLL) during laparoscopic one-anastomosis gastric bypass (OAGB) in patients with morbid obesity. Eligible patients aged 18-65 years with BMI ≥35 kg/m² (non-Asian) or ≥32.5 kg/m² (Asian populations) who were candidates for primary OAGB were randomized 1:1 using a computer-generated randomization sequence with sequentially numbered, opaque sealed envelopes.

In the intervention (TSBL-based) group, total small bowel length (TSBL) was measured intraoperatively from the ligament of Treitz to the ileocecal valve, and BPLL was calculated as 0.35 × TSBL. In the control (BMI-based) group, BPLL was determined using standard fixed lengths based on BMI category (150 cm, 180 cm, or 200 cm). All other surgical steps were identical between groups.

The primary outcome is percentage excess weight loss (%EWL) assessed longitudinally at baseline, 3, 6, and 12 months. Secondary outcomes include percentage total weight loss (%TWL), BMI, BMI loss, improvement of obesity-related comorbidities, and postoperative complications graded using the Clavien-Dindo classification. Statistical analysis uses linear mixed models to evaluate effects of group, time, and group-by-time interaction.

Because blinding of patients and surgeons was not feasible given the nature of the surgical intervention, outcome assessment relied on objective anthropometric and clinical measures. This record reflects a planned interim analysis conducted on the first 75 of a planned total of 100 enrolled patients, with 51 patients having completed 12-month follow-up at the time of this analysis.

Study Type

Interventional

Enrollment (Estimated)

100

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Almaty, Kazakhstan
        • Recruiting
        • JSC "National Scientific Center of Surgery named after A.N. Syzganov"
        • Contact:
        • Principal Investigator:
          • Adil Shokebaev

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Age between 18 and 65 years
  • BMI ≥35 kg/m² in non-Asian populations or ≥32.5 kg/m² in Asian populations
  • Presence or absence of metabolic comorbidities (including type 2 diabetes, hypertension, and dyslipidaemia)
  • Eligibility for primary one-anastomosis gastric bypass (OAGB)
  • Provision of written informed consent

Exclusion Criteria:

  • BMI below the defined thresholds
  • Severe decompensated cardiac, pulmonary, hepatic, or renal disease
  • Acute inflammatory conditions
  • Active gastric or duodenal ulcer
  • Psychiatric disorders or substance abuse
  • Pregnancy or breastfeeding
  • Active malignancy
  • Severe intra-abdominal adhesions due to prior surgery
  • Secondary obesity related to hypothalamic-pituitary-adrenal axis disorders

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: TSBL-Based Group
Biliopancreatic limb length (BPL) individualized based on intraoperatively measured total small bowel length (TSBL), calculated as BPL = 0.35 × TSBL.
Biliopancreatic limb length individualized intraoperatively based on measured total small bowel length (TSBL), calculated as BPL = 0.35 × TSBL, prior to laparoscopic one-anastomosis gastric bypass.
Active Comparator: BMI-Based Group
Biliopancreatic limb length (BPL) determined using standard fixed lengths based on BMI category: 150 cm for BMI 35-39.9, 180 cm for BMI 40-49.9, 200 cm for BMI ≥50.
Biliopancreatic limb length determined using standard fixed lengths based on preoperative BMI category (150 cm, 180 cm, or 200 cm), prior to laparoscopic one-anastomosis gastric bypass.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of Excess Weight Loss (%EWL)
Time Frame: Baseline, 3 months, 6 months, and 12 months post-surgery
EWL defined as the proportion of weight loss relative to excess baseline weight, with ideal body weight defined as BMI 25 kg/m². Assessed longitudinally over time using linear mixed models.
Baseline, 3 months, 6 months, and 12 months post-surgery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of Total Weight Loss (%TWL)
Time Frame: Baseline, 3 months, 6 months, and 12 months post-surgery
TWL assessed as percentage of total body weight loss relative to baseline weight. Assessed longitudinally over time using linear mixed models.
Baseline, 3 months, 6 months, and 12 months post-surgery
BMI Change
Time Frame: Baseline, 3 months, 6 months, and 12 months post-surgery
Change in body mass index (BMI, kg/m²) from baseline over time.
Baseline, 3 months, 6 months, and 12 months post-surgery
BMI Loss (BMIL)
Time Frame: Baseline, 3 months, 6 months, and 12 months post-surgery
Reduction in BMI from baseline, expressed as BMI loss (BMIL).
Baseline, 3 months, 6 months, and 12 months post-surgery
Improvement in Obesity-Related Comorbidities
Time Frame: 12 months post-surgery
Change in obesity-related comorbidities, including hypertension and ischemic heart disease, compared between groups.
12 months post-surgery
Postoperative Complications
Time Frame: 12 months post-surgery
Postoperative complications documented and categorized according to the Clavien-Dindo classification system, including anaemia, hair loss, and bowel movement disorder.
12 months post-surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2023

Primary Completion (Estimated)

November 1, 2027

Study Completion (Estimated)

November 1, 2027

Study Registration Dates

First Submitted

August 27, 2026

First Submitted That Met QC Criteria

August 27, 2026

First Posted (Actual)

September 1, 2026

Study Record Updates

Last Update Posted (Actual)

September 1, 2026

Last Update Submitted That Met QC Criteria

August 27, 2026

Last Verified

August 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Individual participant data underlying the results reported in this article, after deidentification, may be shared with researchers upon reasonable request.

IPD Sharing Time Frame

Data will be available beginning 3 months after article publication, with no defined end date, for researchers who provide a methodologically sound proposal.

IPD Sharing Access Criteria

Data will be available to researchers who provide a methodologically sound proposal, upon reasonable request to the corresponding author (Nurbol Orynbassar, nurbolorynbassar@gmail.com).

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe